Perspective Therapeutics Inc. (CATX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Perspective Therapeutics ...

    AMEX: CATX · Real-Time Price · USD
    3.66
    0.17 (4.87%)
    At close: Oct 03, 2025, 3:59 PM
    3.67
    0.27%
    After-hours: Oct 03, 2025, 07:26 PM EDT

    Perspective Therapeutics Income Statement

    Financials in USD. Fiscal year is July - June.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Jun 30, 2022
    Revenue
    		 n/a 1.43M 7.1M 10.79M
    Cost of Revenue
    		 n/a n/a 5.47M 6.18M
    Gross Profit
    		 n/a 1.43M 1.63M 4.62M
    Operating Income
    		 10.46M -40.94M -15.18M -7.39M
    Interest Income
    		 10.52M 934K 1.12M 119K
    Pretax Income
    		 -81.38M -40.11M -14.67M -7.27M
    Net Income
    		 -79.28M -46.51M -14.67M -7.15M
    Selling & General & Admin
    		 26.61M 21.06M 14.21M 9.43M
    Research & Development
    		 41.64M 21.31M 2.6M 2.58M
    Other Expenses
    		 24.09M n/a n/a n/a
    Operating Expenses
    		 92.34M 42.38M 17.43M 12.01M
    Interest Expense
    		 -48K 84K n/a 119K
    Selling & Marketing Expenses
    		 n/a 97K 3.23M 2.8M
    Cost & Expenses
    		 n/a 42.38M 22.9M 18.19M
    Income Tax Expense
    		 -2.1M -2.65M n/a -119K
    Shares Outstanding (Basic)
    		 64.42M 54.91M 54.91M 54.91M
    Shares Outstanding (Diluted)
    		 64.42M 54.91M 54.91M 54.91M
    EPS (Basic)
    		 -1.23 -0.85 -0.27 -0.13
    EPS (Diluted)
    		 -1.23 -0.85 -0.27 -0.13
    EBITDA
    		 10.46M -39.96M -14.84M -7.39M
    EBIT
    		 -81.42M -40.94M -15.18M n/a
    Depreciation & Amortization
    		 n/a 981K 344K 248K

    Add to Watchlist